diabetic kidney disease
Conditions
Interventions
stachyose group:Oral stachyose 5g,Bid
Sponsors
The First Affiliated Hospital of Zhengzhou University
Eligibility
Sex/Gender
All
Age
18 Years to 80 Years
Inclusion criteria
Inclusion criteria: ?Patients with confirmed type 2 diabetes, aged 18-80 years, BMI =30 kg/m2; ?HbA1C =9%; ?Clinical diagnosis of chronic kidney disease, at least 6 months to meet the criteria for persistent proteinuria (at least 2 examinations), 30 mg/g = urinary albumin to creatinine ratio (UACR) =1000mg/g, and glomerular filtration rate (eGFR) =60ml/min/1.73m2; ?The maximum tolerated dose of angiotensin-converting enzyme inhibitors (ACEI) or angiotensin-receptor blockers (ARBs) was taken for at least 4 weeks before enrollment.
Exclusion criteria
Exclusion criteria: ?Patients taking SGLT2 inhibitors, GLP1 receptor agonists, or finelidone with renal protection; ?Patients with chronic kidney disease of other known etiologies, such as autosomal polycystic kidney disease, lupus nephritis, ANCA-associated vasculitis, etc.; ?Known severe liver disease: AST/ALT more than 3 times the upper normal limit or total bilirubin more than 2 times the upper normal limit; ?Known severe cardiovascular and cerebrovascular disease: NYHA Class 3 or 4 heart failure, acute cardiovascular event, stroke, epilepsy, or thromboembolic event within 1 year; ?Patients with known history of severe hematological diseases, malignant tumors (within 5 years), organ transplant history, and immunosuppressant use; ?In patients with uncontrolled refractory hypertension, systolic blood pressure (SBP) =180mmHg and/or diastolic blood pressure (DBP) =100mmHg; ?Patients with blood potassium level > 5.5mmol/L; ?Women who are pregnant, planning pregnancy or breastfeeding; ? Patients who are allergic or intolerant to oligosaccharides; ? Any medical condition that the investigator believes poses a safety risk to study participants, confuses efficacy or safety assessments, or interferes with study participation.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| UACR;TNF-a;IL-6;AGEs;NGAL;KIM-1; | — |
Secondary
| Measure | Time frame |
|---|---|
| HbA1c;Creatinine;Serum lipid; | — |
Countries
China
Contacts
Public ContactQin Guijun
The First Affiliated Hospital of Zhengzhou University
Outcome results
None listed